Hua Medicine (Shanghai) Ltd Sustainability Reports
Hua Medicine is a biopharmaceutical company engaged in the research, development, and commercialization of global first-in-class oral therapeutics for the treatment of Type 2 diabetes. Its flagship product is HuaTangNing (dorzagliatin tablets), a glucokinase activator targeting glucose sensitivity.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
FIGI: BBG00LVHG0X7
15 reports from 2018 to 2025
